Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05734066
Other study ID # JZP712-101
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 23, 2023
Est. completion date June 2027

Study information

Verified date October 2023
Source Jazz Pharmaceuticals
Contact Clinical Trial Disclosure & Transparency
Phone 215-832-3750
Email ClinicalTrialDisclosure@JazzPharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date June 2027
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 2 Years to 30 Years
Eligibility Key Inclusion Criteria: Age - Participant must meet the following age requirements at the time the informed consent form (ICF) (and assent form, if applicable) is signed: - Phase 1 Part 1: participants must be = 2 to < 18 years of age. - Phase 1 Part 2: participants must be = 2 to = 30 years of age. - Phase 2: participants must be = 2 to = 30 years of age. Type of Participant and Disease Characteristics - Participant has a confirmed solid tumor - The participant has a Lansky/Karnofsky performance status score of = 50%. - The participant has adequate liver function, evidenced by the following laboratory values: - Aspartate aminotransferase (AST), alanine aminotransferase (ALT) = 2.5 × upper limit of normal (ULN). - Total bilirubin = 1.5 × institutional ULN (with the exception of participants with Gilbert's syndrome who must have bilirubin < 3 × institutional ULN). - The participant has adequate bone marrow function, evidenced by the following: - Absolute neutrophil count (ANC) = 1.0 × 109/L (independent of growth factor support within 1 week of screening laboratories). - Platelets = 100 × 109/L (without platelet transfusion within previous 7 days of screening laboratories). - Hemoglobin = 8 g/dL (note: may have been transfused). - The participant has an adequate renal function: - Calculated creatinine clearance (use Cockcroft-Gault formula for participants = 18 years; Schwartz equation for participants < 18 years) = 60 mL/min. - The participant has an adequate cardiac function: - Left ventricular ejection fraction or shortening fraction per institutional norm = institutional lower level of normal. - The participant has creatine phosphokinase = 2.5 × institutional ULN. Weight - The participant has body weight = 15 kg. Sex and Contraceptive/Barrier Requirements Male participants: Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 4 months after the last dose of study intervention: - Refrain from donating sperm. PLUS, either: - Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent. OR - Must agree to use contraception/barrier as detailed below: - Agree to use a male condom with female partner and use of an additional highly effective contraceptive method with a failure rate of < 1% per year when having sexual intercourse with a Woman of childbearing potential (WOCBP) who is not currently pregnant. - Note: male participants who are azoospermic (vasectomized or due to a medical cause) are still required to follow the protocol-specified contraception/barrier criteria. Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: - Is a Woman of nonchildbearing potential (WONCBP). OR - Is a WOCBP and using an acceptable contraceptive method during the study intervention period (at least 6 months after the last dose of study intervention). The investigator should evaluate the potential for contraceptive method failure (eg, noncompliance, recently initiated) in relationship to the first dose of study intervention. - A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 7 days before the first dose of study intervention. - If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. - Additional requirements for pregnancy testing during and after study intervention. - The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. Informed Consent - Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. Key Exclusion Criteria: Medical Conditions - corrected QT interval (QTc) prolongation defined as a QTc = 470 ms using the Bazett formula. - Known symptomatic Central nervous system (CNS) metastases requiring steroids. Participants with previously diagnosed CNS metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to enrollment, have discontinued high dose steroid treatment for these metastases for at least 2 weeks, and are neurologically stable (physiologic doses of steroids and short courses of steroids for other indications are acceptable). - Persisting toxicity related to prior therapy; however, alopecia, sensory neuropathy, hypothyroidism, and rash Grade = 2 are acceptable, and other Grade = 2 adverse events (AEs) not constituting a safety risk based on the investigator's judgement are acceptable. - An uncontrolled intercurrent illness including but not limited to ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy, symptomatic heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Any other major illness that, in the investigator's judgment, could substantially increase the risk associated with participation in this study. - Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high-risk for treatment complications. Prior/Concomitant Therapy - Received prior treatment with lurbinectedin or trabectedin. - Received prior treatment with any investigational product within 4 weeks of first infusion of study intervention. Observational studies are permitted. - Received live or live attenuated vaccines within 4 weeks of the first dose of study treatment or plans to receive live vaccines during study participation. Administration of inactive vaccines or messenger ribonucleic acid (mRNA) vaccines (for example, inactivated influenza vaccines or COVID-19 vaccines) are allowed. - Had major surgery = 4 weeks or radiation therapy = 2 weeks prior to enrollment unless fully recovered. Prior palliative radiotherapy is permitted, provided it was completed at least 2 weeks prior to participant enrollment. - Received prior allogeneic bone marrow transplantation or solid organ transplant. - Received chemotherapy = 3 weeks prior to start of study intervention. Diagnostic Assessments - Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or Polymerase chain reaction (PCR) test for HCV RNA if HCV antibody test is positive). - Human immunodeficiency infection at screening (positive anti-HIV antibody). Other Exclusions - Has a known or suspected hypersensitivity to any of the components of the study intervention. - The participant or parent(s)/guardian(s) is/are unable to comply with the study visit schedule and other protocol requirements, in the opinion of the investigator

Study Design


Intervention

Drug:
Lurbinectedin
Administered as intravenous (IV) infusion once every 3 weeks (Q3W)

Locations

Country Name City State
Canada The Hospital for Sick Children Toronto Ontario
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States MD Anderson Cancer Center Houston Texas
United States Memorial Sloan Kettering New York New York
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Johns Hopkins All Children's Hospital Saint Petersburg Florida
United States Childrens National Hospital Michigan Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Jazz Pharmaceuticals

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) Day -28 up to 15 months postdose.
Primary Phase 1: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) TEAEs are defined as adverse events (AEs) with an onset date on or after the date of the first dose of study treatment. An AE is a TEAE if it occurs up to 30 days after the last dose of study intervention. Post-baseline (Day 1) up to approximately 30 months.
Primary Phase 2: Objective Response Rate (ORR) Based on Investigator Assessment (IA) Day -28 up to a total of 31 months postdose.
Secondary Phase 1: Maximum Plasma Concentration (Cmax) of Lurbinectedin Day 1: Predose up to approximately 168 hours postdose; Days 16, 31, 46: Predose up to approximately 5 minutes postdose.
Secondary Phase 1: Plasma Trough Concentration (Ctrough) of Lurbinectedin Day 1: Predose up to approximately 168 hours postdose; Days 16, 31, 46: Predose up to approximately 5 minutes postdose.
Secondary Phase 1: Plasma Concentration at the End of Infusion (CEOI) of Lurbinectedin Day 1: Predose up to approximately 168 hours postdose; Days 16, 31, 46: Predose up to approximately 5 minutes postdose.
Secondary Phase 1: Area Under the Plasma Concentration-Time Curve (AUC) of Lurbinectedin Day 1: Predose up to approximately 168 hours postdose; Days 16, 31, 46: Predose up to approximately 5 minutes postdose.
Secondary Phase 1: Clearance (CL) of Lurbinectedin Day 1: Predose up to approximately 168 hours postdose; Days 16, 31, 46: Predose up to approximately 5 minutes postdose.
Secondary Phase 1: Volume of Distribution at Steady-State (Vss) of Lurbinectedin Day 1: Predose up to approximately 168 hours postdose; Days 16, 31, 46: Predose up to approximately 5 minutes postdose.
Secondary Phase 1: Objective Response Rate (ORR) Based on Investigator Assessment (IA) Day -28 up to a total of 31 months postdose.
Secondary Phase 1: Progression-Free Survival (PFS) Based on Investigator Assessment (IA) Day -28 up to a total of 31 months postdose.
Secondary Phase 1: Duration of Response (DOR) in Participants with Confirmed Complete Response (CR) or Partial Response (PR) Day -28 up to a total of 31 months postdose.
Secondary Phase 1: Disease Control Rate (DCR) Day -28 up to a total of 31 months postdose.
Secondary Phase 1: Clinical Benefit Rate (CBR) With Stable Disease (SD) for At Least 12 Weeks Day -28 up to a total of 31 months postdose.
Secondary Phase 1: Overall Survival (OS) Post-baseline (Day 1) up to 31 months postdose.
Secondary Phase 2: Plasma Concentration of Lurbinectedin Day 1: Predose up to approximately 168 hours postdose; Days 16, 31, 46: Predose up to approximately 5 minutes postdose.
Secondary Phase 2: Plasma Trough Concentration (Ctrough) of Lurbinectedin Day 1: Predose up to approximately 168 hours postdose; Days 16, 31, 46: Predose up to approximately 5 minutes postdose.
Secondary Phase 2: Plasma Concentration at the End of Infusion (CEOI) of Lurbinectedin Day 1: Predose up to approximately 168 hours postdose; Days 16, 31, 46: Predose up to approximately 5 minutes postdose.
Secondary Phase 2: Clearance (CL) of Lurbinectedin Day 1: Predose up to approximately 168 hours postdose; Days 16, 31, 46: Predose up to approximately 5 minutes postdose.
Secondary Phase 2: Volume of Distribution at Steady-State (Vss) of Lurbinectedin Day 1: Predose up to approximately 168 hours postdose; Days 16, 31, 46: Predose up to approximately 5 minutes postdose.
Secondary Phase 2: Progression-Free Survival (PFS) Based on IA Day -28 up to a total of 31 months postdose.
Secondary Phase 2: Duration of Response (DOR) in Participants with Confirmed Complete Response (CR) or Partial Response (PR) Day -28 up to a total of 31 months postdose.
Secondary Phase 2: Disease Control Rate (DCR) Day -28 up to a total of 31 months postdose.
Secondary Phase 2: Clinical Benefit Rate (CBR) With Stable Disease (SD) for At Least 12 Weeks Day -28 up to a total of 31 months postdose.
Secondary Phase 2: Overall Survival (OS) Post-baseline (Day 1) up to 31 months postdose.
See also
  Status Clinical Trial Phase
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Recruiting NCT06094101 - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) Phase 1/Phase 2
Recruiting NCT06029218 - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy N/A
Completed NCT00743496 - A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma Phase 1
Recruiting NCT04337177 - Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors Phase 1
Active, not recruiting NCT02945800 - Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma Phase 2
Recruiting NCT05968768 - To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) Phase 2
Recruiting NCT06156410 - Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma Phase 1
Terminated NCT02536183 - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Phase 1
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Active, not recruiting NCT03220035 - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT05093322 - A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT02856048 - Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer Phase 2/Phase 3
Withdrawn NCT03880123 - Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Phase 1
Completed NCT04956198 - Drug Sensitivity and Mutation Profiling
Recruiting NCT04791228 - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Phase 2
Recruiting NCT06068075 - Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD N/A
Active, not recruiting NCT03709680 - Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors Phase 1/Phase 2
Completed NCT02044120 - ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma Phase 1
Active, not recruiting NCT01807468 - Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors Phase 2